A matter of scale
A continuing challenge to delivery of gene therapies has been the development of scaleable manufacturing systems for viral vectors. Genovo Inc. is concentrating on process development aspects of viral vector gene therapy through an alliance with the University of Pennsylvania's Institute for Human Gene Therapy (IHGT), which is directed by company founder James Wilson.
"Jim Wilson's lab at the Institute does our early stage research and development," said COO Gary Kurtzman, leaving the company focused on identifying product opportunities and scale-up issues. In exchange for funding, the IHGT provides research, toxicology, animal model, manufacturing and clinical capabilities. Genovo has exclusive rights to technology developed by Wilson's laboratory...